top of page
Pharma R&D
Pharma R&D
Pharma R&D
Pharma R&D
Solving the Problem
GMDx uses advanced AI enabled genomic analytics to identify the likely source and potential clinical impact of disease-causing mutations to support personalized treatment and optimize drug development
The GMDx Breakthrough
Immunotherapy Response Prediciton
The GMDx Innate Immune Fitness (IIF) Score is the most accurate test developed today for predicting how patients will respond to cancer immunotherapy treatments.
The GMDx IFP Outperforms TMB and PD-L1 Tests
IFP
TMB
PD-L1
IFP: Innate Fitness Profile, TMB: Tumor Mutation Burden, PD-L1: Cell-based Biomarker, NPV: Negative predictive value ('who NOT to treat' is what oncologists want to know)
bottom of page